Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

Bimatoprost - Generic Drug Details

« Back to Dashboard

What are the generic drug sources, and freedom to operate, for bimatoprost?

Bimatoprost is the generic ingredient in three branded drugs marketed by Sandoz Inc, Apotex Inc, Alcon Res Ltd, Allergan, and Lupin Ltd, and is included in eight NDAs. There are twenty-five patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

This ingredient has sixty-two patent family members in twenty-one countries.

There are twelve drug master file entries for bimatoprost. Five suppliers are listed for this compound. There are three tentative approvals for this compound.

Summary for Generic Name: bimatoprost

Tradenames:3
Patents:26
Applicants:5
NDAs:8
Drug Master File Entries: see list12
Suppliers / Packagers: see list5
Bulk Api Vendors: see list35
Clinical Trials: see list73
Patent Applications: see list1,655
Therapeutic Class:Ophthalmic Agents
Drug Prices:see low prices
DailyMed Link:bimatoprost at DailyMed

Pharmacology for Ingredient: bimatoprost

Ingredient-typeProstaglandins
Drug ClassProstaglandin Analog

Tentative approvals for BIMATOPROST

Applicant Application No. Form Dosage
► Subscribe► SubscribeSOLUTION; OPHTHALMIC0.03
► Subscribe► SubscribeSOLUTION; OPHTHALMIC0.01%
► Subscribe► SubscribeSOLUTION;OPHTHALMIC0.01%
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan
LUMIGAN
bimatoprost
SOLUTION/DROPS;OPHTHALMIC022184-001Aug 31, 2010RXYesYes8,309,605► Subscribe ► Subscribe
Allergan
LATISSE
bimatoprost
SOLUTION/DROPS;TOPICAL022369-001Dec 24, 2008RXYesYes8,986,715► Subscribe ► Subscribe
Lupin Ltd
BIMATOPROST
bimatoprost
SOLUTION/DROPS;OPHTHALMIC203991-001Feb 20, 2015RXNoYes► Subscribe► Subscribe
Allergan
LATISSE
bimatoprost
SOLUTION/DROPS;TOPICAL022369-001Dec 24, 2008RXYesYes8,263,054► Subscribe ► Subscribe
Apotex Inc
BIMATOPROST
bimatoprost
SOLUTION/DROPS;TOPICAL201894-001Dec 1, 2014RXNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: bimatoprost

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan
LUMIGAN
bimatoprost
SOLUTION/DROPS;OPHTHALMIC022184-001Aug 31, 20105,688,819► Subscribe
Allergan
LUMIGAN
bimatoprost
SOLUTION/DROPS;OPHTHALMIC022184-001Aug 31, 20108,017,655► Subscribe
Allergan
LUMIGAN
bimatoprost
SOLUTION/DROPS;OPHTHALMIC021275-001Mar 16, 20015,688,819► Subscribe
Allergan
LATISSE
bimatoprost
SOLUTION/DROPS;TOPICAL022369-001Dec 24, 20088,017,655► Subscribe
Allergan
LUMIGAN
bimatoprost
SOLUTION/DROPS;OPHTHALMIC022184-001Aug 31, 20106,403,649► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: bimatoprost

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,298,518Method of enhancing hair growth► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: bimatoprost

Country Document Number Estimated Expiration
BrazilPI0607447► Subscribe
Austria309775► Subscribe
China101137383► Subscribe
Japan4143034► Subscribe
Australia2013208002► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: BIMATOPROST

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB02/035United Kingdom► SubscribePRODUCT NAME: BIMATOPROST; REGISTERED: UK EU/1/02/205/001 20020308
00099Netherlands► SubscribePRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION: EU/1/02/205/001 20020308
C0033France► SubscribePRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION:
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc